AEON Biopharma plans IND filing for ABP-450 pharmacodynamic trial in Q4 2026

The company received FDA Type 2b meeting minutes supporting a potentially streamlined biosimilar path versus BOTOX. It plans a Q4 2026 IND submission, Q1 2027 trial initiation and a 2027 return to FDA with an integrated evidence package.